Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita
News
Palvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK
Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes
– Last subject randomized in Phase 2b study-
– Study randomized 433 subjects across 61 sites in 2 countries-
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Findings of REL-1017 Effect on BDNF Plasma Levels to be Presented at the Annual Meeting of the American College of Neuropsychopharmacology
VenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133
VenatoRx is eligible to receive up to $114 million, including upfront milestone payments, in addition to royalties
Mebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate
Preclinical Studies of lead molecules have shown absence of respiratory depression, rewarding behavior, sedation, and constipation associated with traditional opioids
Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
ENB Therapeutics Closes Series A Round of Funding
Remiges led the Series A round of Financing